Animal Vaccines Market to reach USD 16.01 Billion by 2026, exhibiting a CAGR 6.4% | Fortune Business Insights
/
Date12 Oct 2019
Email Print Friendly Share Pune, Oct. 11, 2019 (GLOBE NEWSWIRE) — The global Animal Vaccines Market size is anticipated to rise from a value of... Read More →
QuestCap Grants Stock Options
/
Date12 Oct 2019
Email Print Friendly Share TORONTO, Oct. 11, 2019 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap” or the “Company”) (CSE: QSC) has granted a total of 1,600,000... Read More →
Coca-Cola Consolidated, Inc. Announces Fourth Quarter Dividend
/
Date12 Oct 2019
Email Print Friendly Share CHARLOTTE, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) — Coca-Cola Consolidated, Inc. (NASDAQ: COKE) announced that the Board of Directors has declared... Read More →
First Bancshares, Inc. Announces Third Quarter 2019 Results
/
Date12 Oct 2019
Email Print Friendly Share MOUNTAIN GROVE, Miss., Oct. 11, 2019 (GLOBE NEWSWIRE) — First Bancshares, Inc. (OTCPink – FstBksh: FBSI) (“Company”), the holding company for... Read More →
Gazit Globe Reaffirms its Commitment and Price
/
Date12 Oct 2019
Email Print Friendly Share NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION... Read More →
Ingredion Announces New Time for Third Quarter 2019 Financial Results Conference Call and Webcast on Thursday, October 31, 2019
/
Date12 Oct 2019
Email Print Friendly Share WESTCHESTER, Ill., Oct. 11, 2019 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to diversified... Read More →
Annual Report 2018/19
/
Date12 Oct 2019
Email Print Friendly Share Company announcement No 16, 2019 Reports attached For further information, please contact: ... Read More →
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting
/
Date12 Oct 2019
Email Print Friendly Share — Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks —— Sequential... Read More →